Drug intelligence / Profile preview

AT-05

Development stage: Unknown
Lead developer: Attralus
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

AT-05 is a diagnostic radiopharmaceutical agent that consists of a pan-amyloid binding peptide labeled with technetium-99m (Tc-99m). It is designed for use with single-photon emission computerized tomography (SPECT) imaging to detect amyloid deposits in patients suspected of systemic amyloidosis. The pan-amyloid peptide component enables binding to multiple types of amyloid deposits, supporting broad screening and diagnosis. The drug aims to make amyloidosis imaging more accessible by using Tc-99m, which is widely available for SPECT imaging. Development has been reported by both Amylon Therapeutics and Attralus[1][2].

Brand names: AT-05AT05AT 05
Other names: AT05AT-05AT 05Amylon Therapeutics AT-05

Beyond the preview

Go deeper on AT-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-05.

Explore the full profile